AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

This article originally appeared here.
Share this content:
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

TUESDAY, Nov. 15, 2016 (HealthDay News) -- A new injectable medication called inclisiran cuts low-density lipoprotein (LDL) cholesterol by half or more, and the effect could last for four to six months, according to research presented at the annual meeting of the American Heart Association, held from Nov. 12 to 16 in New Orleans.

Inclisiran is a next-level PCSK9 inhibitor, which works on a genetic level to prevent cells from producing PCSK9, study presenter Kausik Ray, M.D., of Imperial College London, told HealthDay. The inclisiran clinical trial involved 501 patients who were assigned to either a control group or one of four groups that received different doses of the drug.

One dose of inclisiran at 300 mg or greater caused a 51 percent drop in LDL cholesterol that lasted at least 90 days, while two doses caused a 57 percent reduction that lasted up to six months, Ray reported. Based on these results, Ray and his colleagues estimate patients would only need an inclisiran injection two or three times a year to control their cholesterol.

Side effects from the medication were similar to those reported by patients taking either statins or placebos, the researchers reported. Muscle aches, headache, fatigue, back pain, high blood pressure, diarrhea, and dizziness were the most common side effects.

The study was funded by The Medicines Company, the manufacturer of inclisiran.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »